buprenorphine sublingual spray / Insys Therap - LARVOL DELTA

Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive. (PubMed, Pharmaceutics) - "The exploratory growth phase (1983-1993) was marked by the use of nitroglycerin to treat angina, calcium channel blockers to treat hypertension, ACE inhibitors to treat heart conditions, the use of opioids in pain management therapy, and peptide and hormonal therapy. The innovation and integration phase (2010-2025) was marked by the use of nanoparticles, multilayered mucoadhesive systems, pediatric formulations (fast-dissolving films and tablets), immunotherapy and vaccine delivery, and a broad spectrum of therapeutic agents, such as steroids, antifungals, cannabinoids, antidepressants, antipsychotics, and narcotics (e.g., buprenorphine and apomorphine), novel formulations of fentanyl and diazepam for pain and seizure control, and the introduction of buccal vitamin D3 sprays. Understanding the history of sublingual and buccal delivery demonstrates a growing area of research focused on enhancing mucosal drug delivery for achieving local and systemic therapeutic benefits."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy • Hypertension • Pain • Pediatrics • Substance Abuse

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers (clinicaltrials.gov) - P1; N=47; Completed; Sponsor: INSYS Therapeutics Inc; Recruiting ➔ Completed; N=24 ➔ 47

Enrollment change • Trial completion • Biosimilar

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain (clinicaltrials.gov) - P3; N=312; Recruiting; Sponsor: INSYS Therapeutics Inc; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Pain